
APOE4 STATUS AND COGNITIVE FUNCTION
IN MIDDLE-AGED AND ELDERLY PEOPLE Pavel N.A.1, Paun M.R.2, Matei P.V.1,2, Dutu I.1, Tudose C.1,2 *Corresponding Author: Valentin P. Matei, Associate Proffesor, MD, PhD. 2nd Ward of “Prof. Dr. Alexandru
Obregia” Hospital, Berceni Street no 10, Bucharest, Romania. E-mail: valipmatei@yahoo.com page: 6 download article in pdf format
|
Abstract
Introduction: APOE is one of the prominent genes
involved in the increased risk of developing Alzheimer’s
disease, but its effect on cognition in patients who are not
yet diagnosed with dementia or mild cognitive impairment
is relatively understudied. We aimed to examine the effect
of ApoE4 on cognitive performance in unimpaired middleaged
and elderly persons.
Materials and methods: Our study included 51
cognitively unimpaired participants divided into ApoE4
positive patients and controls by APOE genotyping. The
following clinical and demographic characteristics were
collected: age, gender, education, social status, BMI, history
of medical or psychiatric disorders. Patients with
current anxiety or depressive disorders were excluded.
Cognitive function was evaluated using MMSE, Rey Auditory-
Verbal Learning Test, Rey Complex Figure test,
TMT A and B and verbal fluency test. The two groups
were matched for age, sex, and education. Categorial data
was analyzed using Chi-Square and continuous data using
Student-T test (parametric variables) or Mann-Whitney
test (non-parametric variables). Statistical significance
was considered at p≤.05.
Results: There were 11 (21.6%) ApoE4 positive patients
and 40 (78.4%) controls. There were no significant
differences between the groups regarding socio-demographic
and clinical characteristics. The ApoE4 positive
group performed slightly worse on cognitive evaluations
compared to controls but only the mean scores of the Rey
Complex Figure Test – Memory reached statistical significance
(p=.019).
Conclusion: Cognitive evaluation generally rendered
lower scores in the ApoE4 group compared to the control
group. However, only visual memory impairment scores
were significantly lower in the ApoE4 positive individuals
than in controls.
|
|
|
|



 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|
|